**WELCOME**

Dear colleagues,

We are pleased to announce the 8th edition of the International Course on Transplantation and Cell Therapy to be held in Barcelona on 8-10 September 2023. We hope it will be at least as successful as the previous edition, the first one in face-to-face format after the COVID-19 pandemic.

The course has a clear objective, the critical review of the most outstanding aspects in the field of hematopoietic progenitor transplantation and other cell therapy strategies. Through different presentations made by experts in the field, in an agile and interactive format, the aim of this event is the direct participation of young people through the presentation of clinical cases, among other activities.

As last year, the course will take place over three days with three distinct tracks in order to embrace as many professionals as possible; the adult and pediatric tracks will focus on the specific peculiarities of these two populations of patients, and a third track will focus on all aspects of these treatment strategies that are of key interest for the nurses. This year we are aiming for a simultaneous translation from English to Spanish for the Nurses Sessions in order to increase our reach in this last specific group of health care professionals.

We hope that the course will be of interest to you and that you will be encouraged to collaborate; your participation will undoubtedly be a key factor in its success.

Best regards,

The Organizing Committee
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chairs/Speakers</th>
</tr>
</thead>
</table>
| 09:00 - 09:50 | Welcome and introduction  
 Anna Sureda (SP) & Nico Cagelman (DE) |                                                                                 |
| 09:00 - 09:20 | ITCTC introduction and what is EBMT                                        | Anna Sureda (SP)                                                                |
| 09:20 - 09:40 | A brief overview of JACIE                                                  | Nico Cagelman (DE)                                                              |
| 09:40 - 09:50 | Q&A                                                                       | Tuula Rintala (UK)                                                              |
| 09:50 - 11:30 | Session 1: Preparing for transplant  
 Florent Malard (FR) & Carmelo Gurnari (IT) |                                                                                 |
| 09:50 - 10:10 | HLA system and impact on donor selection: what’s new?                     | Neema Mayor (UK)                                                               |
| 10:10 - 10:30 | Conditioning regimens: a practical guide                                   | Florent Malard (FR)                                                            |
| 10:30 - 10:50 | What a transplant physician should know about germ line predisposition traits for donor selection | Carmelo Gurnari (IT)                                                           |
| 10:50 - 11:10 | Mobilization and collection / HSC cryopreservation and quality assessment | Oscar M. Pello (SP)                                                            |
| 11:10 - 11:30 | Discussion, Q&A                                                           |                                                                                 |
| 11:30 - 12:00 | Coffee Break                                                              |                                                                                 |
| 12:00 - 13:00 | Session 2: Monitoring after transplant  
 Florent Malard (FR) |                                                                                 |
| 12:00 - 12:20 | Measurable residual disease, chimerism assessment                         | Alexandros Spyridonidis (GR)                                                   |
| 12:20 - 12:40 | Mechanisms of leukemia immune evasion and their role in post-transplant relapse | Cristina Toffalori (IT)                                                        |
| 12:40 - 12:50 | Case report: Adoptive immunotherapy with cytokine induced killer cells for Philadelphia-positive acute lymphoblastic leukemia relapsed after allogeneic stem cell transplantation and unresponsive to tyrosine kinase inhibitors. A case report. | Federica Frenza (IT)                                                            |
| 12:50 - 13:00 | Discussion, Q&A                                                           |                                                                                 |
| 13:00 - 13:45 | Lunch Break                                                               |                                                                                 |
| 13:45 - 14:30 | Industry Symposium on “Post-transplant – How to treat GvHD with ECP in 2023” | Kindly sponsored by Therakos                                                   |
| 13:45 - 13:50 | Introduction                                                              | Anna Sureda (SP)                                                               |
| 13:50 - 14:05 | Post-transplant – How to treat acute GvHD with ECP in 2023                | Florent Malard (FR)                                                            |
| 14:05 - 14:20 | Post-transplant – How to treat chronic GvHD with ECP in 2023              | Nicolaus Kröger (DE)                                                           |
| 14:20 - 14:30 | Discussion                                                               |                                                                                 |
## Preliminary Programme

### 14:30 – 16:00  
**Session 3: GvHD**  
*Chairs: Olaf Penack (DE) & Kristin Rathje (DE)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 – 14:50</td>
<td>Prophylaxis</td>
<td>Florent Malard (FR)</td>
</tr>
<tr>
<td>14:50 – 15:10</td>
<td>Treatment Acute GvHD</td>
<td>Florent Malard (FR)</td>
</tr>
<tr>
<td>15:10 – 15:30</td>
<td>Treatment Chronic GvHD</td>
<td>Olaf Penack (DE)</td>
</tr>
<tr>
<td>15:30 – 15:40</td>
<td>Case report: Polymyositis: A Rare Manifestation of Chronic GVHD</td>
<td>Ang Chieh Hwee (SG)</td>
</tr>
<tr>
<td>15:40 – 15:50</td>
<td>Case report: Peeling and laser therapy for management of face hyperpigmentation after chronic graft versus host disease: a case report</td>
<td>Lucas Vogt Cota (BR)</td>
</tr>
<tr>
<td>15:50 – 16:00</td>
<td>Discussion, Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

### 16:00 – 16:30  
**Coffee Break**

### 16:30 – 18:00  
**Session 4: Infections and other complications after transplant**  
*Chairs: Rafael de la Cámara (SP) & Sheila Torrado (SP)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30 – 16:50</td>
<td>Graft failure and poor graft function</td>
<td>Annalisa Ruggeri (IT)</td>
</tr>
<tr>
<td>16:50 – 17:10</td>
<td>Respiratory virus</td>
<td>José Luis Piñana (SP)</td>
</tr>
<tr>
<td>17:10 – 17:30</td>
<td>CMV</td>
<td>Per Ljungman (SE)</td>
</tr>
<tr>
<td>17:30 – 17:40</td>
<td>Case report: Haploidential transplant recipient with severe pneumonia by Respiratory Syncytial Virus (RSV): a case report.</td>
<td>Gloria Catalano (IT)</td>
</tr>
<tr>
<td>17:40 – 17:50</td>
<td>Case report: Cerebral Toxoplasmosis After Allogenic Stem Cell Transplant In A Patient Living With HIV</td>
<td>Tien Gen Wong (MY)</td>
</tr>
<tr>
<td>17:50 – 18:00</td>
<td>Discussion, Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

### 18:15 – 19:30  
**Welcome reception & poster walk**
8th International Transplant and Cellular Therapy Course

Preliminary Programme

Barcelona, Spain
8-10 September 2023

Saturday, 9 September 2023
Plenary room: Paraninfo | Adults’ Track

08:45 – 10:15  Session 5: Indications for HCT in Adults (I)
Chair: Fabio Ciceri (IT) & Esra Gülüderen (TR)
08:45 - 09:15  Introductory Case + The role of HCT in AML  Eolia Brissot (FR)
09:15 - 09:45  Introductory Case + HCT in ALL: where do we stand?  Sebastian Ciebel (PL)
09:45 - 09:55  Case report: Refractory acute myeloid leukemia with complex karyotype in young male  Piotr Piętowski (PL)
09:55 - 10:05  Case report: Rapid turnaround of germline WGS facilitating donor selection in AML with CEBPA mutation.  Sally Thomas (UK)
10:05 - 10:15  Discussion

10:15 – 10:45  Coffee Break

10:45 – 12:15  Session 6: Indications for HCT in Adults (II)
Chair: Donal McLornan (UK) & Alex Rampotas (UK)
10:45 - 11:15  Introductory Case + HCT in MDS in the new molecular era of IPSS-M  Kristin Rathje (DE)
11:15 - 11:45  Introductory Case + HCT in MPD: a state of the art and considerations on its role as opposed to conservative strategies  Nicolaus Kröger (DE)
11:45 - 11:55  Case report: Successful salvage of Myelofibrosis with Frank Relapse Post-Allogeneic Stem Cell Transplantation Using Adoptive Immunotherapy with DLI  Angela Hwang (UK)
11:55 - 12:05  Case report: Haploidentical hematopoietic cell transplantation for blast phase myelofibrosis  Donal McLornan (UK)
12:05 - 12:15  Discussion, Q&A

12:15 – 13:00  Lunch Break

13:00 – 14:30  Session 7: Indications for HCT in Adults (III)
Chair: Raffaella Greco (IT) & Rosamaria Nitti (IT)
13:00 - 13:30  Introductory Case + HCT in PCD: who should we candidate?  Edward Jones (IE)
13:30 - 14:00  Introductory Case + HCT in AID: an overview  Patrick Hayden (IE)
14:00 - 14:10  Case report: Multi-organ chronic graft-vs-host-disease mimicking MDAS Autoantibody-Associated Dermatomyositis  Andrea Acerbis (IT)
14:10 - 14:20  Case report: Allogeneic hematopoietic stem cells transplantation in adult patient with immunodeficiency caused by hemizygous mutation of the XIAP gene - a case report  Nicolò Rampi (IT)
14:20 - 14:30  Discussion, Q&A

14:30 – 15:00  Coffee Break
15:00 – 16:15  **Session 8: Long-term survivorship after HCT (joint session)**  
*Chairs: Anna Sureda (SP) & Alexandra Martínez (SP)*

15:00 -15:30  Late Complications: an overview of Endocrine and fertility complications  
Annalisa Pavigliani (SP)

15:30 -15:50  Post-transplant therapeutic strategies in acute leukemias  
Aron Nagler (IL)

15:50 - 16:00  Case report: Simultaneous Presentation of VOD/SOS and PTLD: a Case  
Report of Two Uncommon Complications after Allogeneic Stem Cell Transplantation  
Federica Frenza (IT)

16:00 – 16:15  Discussion

16:15 – 16:45  **Keynote Lecture**  
*Chair: Anna Sureda (SP)*

From Allo transplant to Gene therapy in SCD / Thalassemia  
Selim Corbacioglu (DE)
### 8th International Transplant and Cellular Therapy Course

**Preliminary Programme**

**Barcelona, Spain**

**8-10 September 2023**

#### Saturday, 9 September 2023

**Aula 2 | Paediatrics’ track**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chairs/Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45 - 10:15</td>
<td><strong>Session 1: Acute Leukaemia in Children</strong></td>
<td><strong>Chairs: Krzysztof Kałwak (PL) &amp; Petr Sedlacek (CZ)</strong></td>
</tr>
<tr>
<td>08:45 - 09:05</td>
<td>HCT for ALL: why, when and how?</td>
<td>Petr Sedlacek (CZ)</td>
</tr>
<tr>
<td>09:05 - 09:25</td>
<td>AML in Children</td>
<td>Robert Wynn (UK)</td>
</tr>
<tr>
<td>09:25 - 09:45</td>
<td>Paediatric CAR-T Cell Therapy: where do we stand?</td>
<td>Krzysztof Kałwak (PL)</td>
</tr>
<tr>
<td>09:45 - 09:55</td>
<td>Case presentation: Excellent outcome of children with pB-ALL relapsing post HSCT, who had a very low disease burden at the time of LDC before CAR-T cell infusion</td>
<td>Karolina Liszka (PL)</td>
</tr>
<tr>
<td>09:55 - 10:15</td>
<td>Discussion, Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>10:15 - 10:45</td>
<td><strong>Coffee Break</strong></td>
<td></td>
</tr>
<tr>
<td>10:45 - 12:15</td>
<td><strong>Session 2: Inborn Errors</strong></td>
<td><strong>Chairs: Bénédicte Neven (FR) &amp; Robert Wynn (UK)</strong></td>
</tr>
<tr>
<td>10:45 - 11:05</td>
<td>HCT and gene therapy of Metabolic Disease</td>
<td>Robert Wynn (UK)</td>
</tr>
<tr>
<td>11:05 - 11:25</td>
<td>HCT for immunodeficiencies</td>
<td>Bénédicte Neven (FR)</td>
</tr>
<tr>
<td>11:25 - 11:45</td>
<td>HCT for immune dysregulation</td>
<td>Bénédicte Neven (FR)</td>
</tr>
<tr>
<td>11:45 - 11:55</td>
<td>Case presentation: Simultaneous haploidirectional HSCT in 2 brothers with chronic granulomatous disease using PT-Cy - a case report</td>
<td>Pik Ki Chan (CH)</td>
</tr>
<tr>
<td>11:55 - 12:15</td>
<td>Discussion, Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>12:15 - 13:00</td>
<td><strong>Lunch Break</strong></td>
<td></td>
</tr>
<tr>
<td>13:00 - 14:30</td>
<td><strong>Session 3: Bone marrow failure, myelodysplastic syndromes, and selected complications</strong></td>
<td><strong>Chairs: Carlo Dufour (IT) &amp; Katharina Kleinschmidt (DE)</strong></td>
</tr>
<tr>
<td>13:00 - 13:20</td>
<td>Congenital bone marrow failure syndromes</td>
<td>Carlo Dufour (IT)</td>
</tr>
<tr>
<td>13:20 - 13:40</td>
<td>MDS and 3MML</td>
<td>Dominik Turkiewicz (SE)</td>
</tr>
<tr>
<td>13:40 - 14:00</td>
<td>What is new in paediatric VOD In 2023?</td>
<td>Katharina Kleinschmidt (DE)</td>
</tr>
<tr>
<td>14:00 - 14:10</td>
<td>Case presentation: Allogenic haematopoietic stem cell transplant (HSCT) in a child with somatic K-RAS Positive Juvenile Myelomonocytic Leukaemia (JML) and challenging secondary haemo-phagocytic lymphohistocytosis (HLH)</td>
<td>Purushotham Ramachandran (UK)</td>
</tr>
<tr>
<td>14:10 - 14:30</td>
<td>Discussion, Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>
### Preliminary Programme

**8th International Transplant and Cellular Therapy Course**

Barcelona, Spain

8-10 September 2023

#### Saturday, 9 September 2023

**Aula Magna | Nurses’ track**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 1: Preparation, cell collection, conditioning, and infusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45 - 10:15</td>
<td>Chairs: Hilda Mekelenkamp (NL) &amp; Michelle Kenyon (UK)</td>
</tr>
<tr>
<td>08:45 - 09:05</td>
<td>Right donor, right patient, right time</td>
</tr>
<tr>
<td>09:05 - 09:25</td>
<td>Role of the apheresis nurse - more than just cell collection</td>
</tr>
<tr>
<td>09:25 - 09:45</td>
<td>Conditioning regimens - different approaches and why</td>
</tr>
<tr>
<td>09:45 - 10:05</td>
<td>Cell infusion: stem cell, CART and lymphocyte infusions - exploring the differences</td>
</tr>
<tr>
<td>10:05 - 10:15</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>10:15 - 10:45</td>
<td>Coffee Break</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 2: Post-infusion care</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 - 12:15</td>
<td>Chairs: Julia Ruiz Pato (SP) &amp; Daniel Kisielewski (DE)</td>
</tr>
<tr>
<td>10:45 - 11:05</td>
<td>Nutritional support - the current guidance</td>
</tr>
<tr>
<td>11:05 - 11:25</td>
<td>CVCs - evidencing best practice in 2023</td>
</tr>
<tr>
<td>11:25 - 11:45</td>
<td>Neutropenic fever and the sepsis 6</td>
</tr>
<tr>
<td>11:45 - 12:05</td>
<td>Oral Mucositis - prevention, assessment and care</td>
</tr>
<tr>
<td>12:05 - 12:15</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>12:15 - 13:00</td>
<td>Lunch Break</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 3: Supportive care</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 - 14:30</td>
<td>Chairs: Thomas Jezequel (FR) &amp; Sandra Schönfeld (CH)</td>
</tr>
<tr>
<td>13:00 - 13:20</td>
<td>Big issues: Sex and sexuality after transplant</td>
</tr>
<tr>
<td>13:20 - 13:40</td>
<td>Fungal infections and treatment</td>
</tr>
<tr>
<td>13:40 - 14:00</td>
<td>Chimerism</td>
</tr>
<tr>
<td>14:00 - 14:20</td>
<td>Advanced care planning conversations and palliative care: where they fit</td>
</tr>
<tr>
<td>14:20 - 14:30</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>14:30 - 15:15</td>
<td>Coffee Break</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 4: Essential update</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15 - 16:25</td>
<td>Chairs: Lidia Hurtado (IL) &amp; Marijke Quaghebeur (BE)</td>
</tr>
<tr>
<td>15:15 - 15:30</td>
<td>GVHD new therapies and old assessment</td>
</tr>
<tr>
<td>15:15 - 15:30</td>
<td>Paediatric update</td>
</tr>
<tr>
<td>15:45 - 16:00</td>
<td>Advanced therapies: where are we now with CART and BITEs</td>
</tr>
<tr>
<td>16:00 - 16:15</td>
<td>Haemorrhagic cystitis - the role of PTCy, other causes, care, and consequences</td>
</tr>
<tr>
<td>16:15 - 16:25</td>
<td>Q&amp;A</td>
</tr>
</tbody>
</table>
08:45 - 09:40  Session 9: Preparing for CAR-T
   Chairs: Maeve O’Reilly (UK) & Candice Hendricks (ZA)
   08:45 - 09:05  Safety issues of gene therapy and gene editing  Fabio Ciceri (IT)
   09:05 - 09:25  Principles of CAR T and TCR editing  Matteo Doglio (IT)
   09:25 - 09:40  Discussion

09:40 - 11:00  Session 10: Early and late complications
   Chairs: Raffaela Greco (IT) & Justin Du Toit (ZA)
   09:40 - 10:00  Early complications post-CAR-T infusion  Maeve O’Reilly (UK)
   10:00 - 10:10  Case Presentation: Acute Myeloid Leukemia Development after Long-Lasting Immune Effector Cell-Associated Hematotoxicity  Elisa Linnea Lindfors Rossi (SE)
   10:10 - 10:30  Late complications Hematotoxicity  Marion Subklewe (DE)
   10:30 - 10:40  Case Presentation: Challenges in Chimeric Antigen Receptor-T cell product administration in a high tumor-burden elderly patient with mantle-cell lymphoma  Umberto Pizzano (IT)
   10:40 - 11:00  Discussion

11:00 - 11:30  Coffee Break

11:30 - 13:00  Session 11: Indications for CAR-T in Adults
   Chairs: Valentin Ortiz-Maldonado (SP) & Natacha Bolaños (SP)
   11:30 - 11:50  CAR-T in ALL  Nicolas Boissel (FR)
   11:50 - 12:10  CAR-T in PCD  Nico Gagelmann (DE)
   12:10 - 12:30  HCT & CAR-T for lymphomas  Anna Sureda (SP)
   12:30 - 12:40  Case Presentation: Double CART19/ALLO-HCT tandem as a management strategy for very advanced stage relapsed / refractory adult b-cell acute lymphoblastic leukemia  Helena Brillembourg (SP)
   12:40 - 12:50  Case Presentation: CAR-T cell therapy for refractory lymphoma and sle: a promising breakthrough  Carolina Arevalo (SP)
   12:50 - 13:00  Discussion

13:00 - 13:15  Closing remarks & Poster award
Andrea Acerbis (Italy)

Andrea Acerbis received his medical degree from Università degli Studi in Milan, Italy, in 2019, with a thesis concerning the applicability of allogeneic stem cell transplantation in high-risk chronic lymphocytic leukemia after therapy with BCR inhibitors. Since 2021, he is a resident physician in Hematology and Bone Marrow Transplant Unit in San Raffaele Hospital, Milan, under the supervision of Professor Fabio Ciceri, with interest in hematopoietic stem cell transplantation, unrelated bone marrow donor search and cellular and gene therapies. He is author of abstracts and presenter of oral and posters at international meetings.

Katie Ahern (Ireland)

St. James University Hospital in Dublin, Ireland.

Chieh Hwee Ang (Singapore)

Associate Consultant in the Department of Haematology in the Singapore General Hospital.

Carolina Arevalo (Spain)

Department of Hematology, Catalan Institute of Oncology, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain

Nicolas Boissel (France)

Nicolas Boissel is Head of the Adolescent and Young Adults Unit, Department of Haematology, Saint-Louis Hospital, and Professor of Medicine at Université de Paris Cité, France. After beginning his career as a research fellow at the Pasteur Institute and as an intern at Paris Municipal Hospitals, he did a PhD at the Department of Immunology at Saint-Louis Hospital in 2002 while completing his MD at the University of Paris VI.
In 2005, he went on to become Assistant Professor at Saint-Louis hospital in the Acute Leukemia unit headed by Professor Hervé Dombret, before taking up his current position in 2010. He is engaged in therapeutics for patients with bone marrow disorders including acute leukaemia, lymphoma, and bone marrow failure, with a specific focus of adolescent and young adult comprehensive care. He is the chairman of the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) and former president of the French Oncohematology Group for Adolescents and Young Adults (GO-AJA). He is involved in many trials designed to improve the outcome of acute leukaemia patients. His clinical research interests include the role of new oncogenic events and minimal-residual disease to stratify therapeutic approaches in acute leukaemia, and the development of immunotherapy in the field.

Styliani Bouziana (United Kingdom)

Dr Stella Bouziana is a Hematologist at King’s College Hospital, London, UK. She obtained her medical degree and PhD from the Aristotle University of Thessaloniki, Greece. She specializes in the fields of Cellular Therapies and Stem Cell Transplantation. In addition to publishing in peer-reviewed articles, she also serves as an editor, board member and reviewer in multiple prestigious journals.

Ida Bremer Ophorst (The Netherlands)

I am a pediatric oncology nurse and nurse researcher and work at a stem cell transplantation and hematology ward in the Princess Maxima Center. My focus is among other things, oral mucositis and Quality improvement in daily care.

Helena Brillembourg (Spain)

Hospital Clinic in Barcelona, Spain
Eolia Brissot (France)

Eolia Brissot, MD, PhD, is Associate-Professor of Hematology and works at Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and Sorbonne University (Paris, France). She attended the University of Nantes, France, where she completed her medical degree. She then undertook a PhD at Sorbonne University in Paris, France, before working at the laboratory of hematologic stem cell transplantation unit at the National Institute of Health, Bethesda, USA with a Fulbright grant.

She is also Secretary of the ALWP of the European Society for Blood and Marrow Transplantation (EBMT). She has a special clinical and research focus on the different aspects of therapy of acute lymphoblastic leukemia and on infectious complications. Dr Eolia Brissot has published more than 130 peer-reviewed articles in the field of stem cell transplantation and leukemia, in different hematology and immunology journals. She also serves as an Associate Editor for Current research in translational Medicine, as a member of the editorial board of Bone Marrow Transplantation journal and Clinical Hematology International journal, and as a regular reviewer in different immunology, hematology, and cancer journals such as Lancet Haematology and Journal Hematology Oncology.

Gloria Catalano (Italy)

Hematology resident in San Raffaele Hospital, Milano, Italy.

Pik Ki Chan (Italy)

Department of Stem Cell Transplantation, University Children's Hospital Zurich, Switzerland
Fabio Ciceri (Italy)

Professor Fabio Ciceri is active in the hematological field, where he deals with the treatment of acute leukaemia, aggressive lymphomas, myeloproliferative neoplasms, and hemoglobinopathies. PI of several trials in stem cell transplantation and gene therapy for the treatment of blood cancers, non-neoplastic diseases such as autoimmune, neuroinflammatory, genetic diseases including hemoglobinopathies. Chair of Acute Leukemia Working Party of EBMT (www.ebmt.org) President of AISPO NGO (www.aispo.org) and active in health care cooperation projects in Africa and Middle East.

Selim Corbacioglu (Germany)

Selim Corbacioglu is Professor and Chair of the Department of Hematology, Oncology and Stem Cell Transplantation at the Children’s Hospital in Regensburg, Germany. His major research interest is focused on curative options for hemoglobinopathies and transplant-related systemic endothelial complications. As the PI of several multi-centre interventional trials in children, he is the PI for a prospective international trial to evaluate haploidentical HSCT in sickle cell disease.

He was also one of the lead investigators of the Crisp/Cas9 based gene editing trial in sickle cell disease and thalassemia, where this new approach was successfully applied first-in-man in a patient with thalassemia in his institution. The recipient of the Van Bekkum Award of the EMBT in 2010, Professor Corbacioglu is author of numerous peer-reviewed articles published in the New England Journal of Medicine, Lancet, Blood, Leukaemia and Bone Marrow Transplantation among others. During his term as the scientific council chair and the Chair of the Pediatric Disease Working Party of the EBMT, one of his major contributions was the inauguration of the Hemoglobinopathy Working Party (HGP) of the EBMT.
Rafael de la Camara (Spain)

I am a haematologist involved in haemopoietic transplant activities for the last 35 years. My main areas of interest and research are the infectious complications of SCT patients, particularly CMV infections. Since May 2020 I have had the honour of being the chair of the Infectious Diseases Working Party of EBMT.

Maaike de Ruijter (The Netherlands)

Maaike de Ruijter is working as a nurse practitioner in the Netherlands at Amsterdam UMC location VUMC. Her areas of focus are: Outpatient ward; patients with multiple myeloma and lymphoma, referred for high dose chemotherapy and autologous stem cell transplantation or for new therapy options as bispecific antibodies or CAR-T cell therapy. Support patients after autologous stem cell transplantation, focused on regaining as much quality of life.

She is the WP-nurse of the EBMT Chronic Malignancies Working Party and was until March 2019 the chair of the Special Interest Group Hematology Netherlands. Recently she started in a new role as Working Party Lead Nurse. A new created role to support the WP nurses into their role and to assist with project development, education, research and to provide peer support to the WP nurses. Publication The EBMT Immune Effector Cell Nursing Guidelines on CAR-T Therapy: A Framework for Patient Care and Managing Common Toxicities Rose Ellard, Michelle Kenyon, Daphna Hutt, Erik Aerts, Maaike de Ruijter, Christian Chabannon, Mohamad Mohty, Silvia Montoto, Elisabeth Wallhult & John Murray Clinical Hematology International (08 July 2022). Passion: To develop masterclasses/educational courses for nurses and nurse practitioners, and create opportunities to let our knowledge grow as nurses. She also want to emphasize the importance of specialized nurses care for patients receiving treatment at the outpatient ward.
Rafael de la Camara (Spain)

I am a haematologist involved in haemopoietic transplant activities for the last 35 years. My main areas of interest and research are the infectious complications of SCT patients, particularly CMV infections. Since May 2020 I have had the honour of being the chair of the Infectious Diseases Working Party of EBMT.

Johan De Munter (Spain)

Johan De Munter is currently working as a nurse manager at the University Hospital Ghent Cancer Center. He has been a registered nurse in oncology-haematology for 22 years, was a member and board member of the Flemish Society of cancer nurses, is a member of BHS nurses group and an individual member of EONS since entering the profession. He specialised and obtained a postgraduate degree in pain management and continued his studies with a postgraduate degree in oncology.

In 2010, he transferred to University Hospital Ghent to continue in a nurse consultant role for the haematology/stem cell transplant unit and has since expanded his expertise in healthcare provision and patient education, supportive care needs, adolescents and young adults with cancer, transition and survivorship care with a focus on evidence-based cancer nursing, quality of care, advocacy and communication. He continued to specialise and completed a postgraduate certificate in Teenage/Young Adult Cancer Care at Coventry University in the UK, and finished a postgraduate degree in leadership. He is currently a board member in the Majinhuis, a community support home for people affected by cancer. He is also a member of the steering committee and a permanent teacher on the Flemish training program for adolescents and young adults, and is a frequent guest teacher in various postgraduate courses for nurses and allied healthcare professionals. He is co-chair of the Flemish strategic AYA movement advisory group, an active member of the Belgian Haematology Society nurses committee, a member of the SIOP Europe AYA Committee, and a member of the Belgian Federal Council of Nursing.

He became the President of EONS in January 2021 and is committed to enhancing the field of nursing by building together and advocating for innovative care, education and research for the benefit of all cancer nurses and improvement of the overall quality of life for people with cancer.
Maaike de Ruijter (The Netherlands)

Maaike de Ruijter is working as a nurse practitioner in the Netherlands at Amsterdam UMC location VUMC. Her areas of focus are: Outpatient ward; patients with multiple myeloma and lymphoma, referred for high dose chemotherapy and autologous stem cell transplantation or for new therapy options as bispecific antibodies or CAR-T cell therapy. Support patients after autologous stem cell transplantation, focused on regaining as much quality of life.

She is the WP-nurse of the EBMT Chronic Malignancies Working Party and was until march 2019 the chair of the Special Interest Group Hematology Netherlands. Recently she started in a new role as Working Party Lead Nurse. A new created role to support the WP nurses into their role and to assist with project development, education, research and to provide peer support to the WP nurses. Publication The EBMT Immune Effector Cell Nursing Guidelines on CAR-T Therapy: A Framework for Patient Care and Managing Common Toxicities Rose Ellard, Michelle Kenyon, Daphna Hutt, Erik Aerts, Maaike de Ruijter, Christian Chabannon, Mohamad Mohty, Silvia Montoto, Elisabeth Wallhult & John Murray Clinical Hematology International (08 july 2022). Passion: To develop masterclasses/educational courses for nurses and nurse practitioners, and create opportunities to let our knowledge grow as nurses. She also want to emphasize the importance of specialized nurses care for patients who receiving treatment at the outpatient ward.

Matteo Doglio (Italy)

San Raffaele Hospital in Milan, Italy.

Justin du Toit (South Africa)

Dr. Justin du Toit MBChB Pretoria (2005), FCP(SA) 2013), MSc(Rotterdam) (2015),Cert ClinHaem(Phys) (SA) (2018) Justin du Toit was awarded the MBChB degree from the University of Pretoria in 2005. He enrolled for post - graduate studies in Internal Medicine at the University of Cape Town and qualified as a Specialist Physician in 2013. He obtained a scholarship to pursue a Master's degree of Science in the field of Infection and Immunology at Erasmus Medical Centre in Rotterdam, the Netherlands for a period of two years.
During that time he completed two internships in the Viroscience laboratory studying interactions between viruses and the human immune system. In 2015 he returned to South Africa to further his studies in the field of Clinical Haematology at the University of Cape Town. He graduated as a Clinical Haematologist in 2018 and received the Mabashan prize that same year for the best student in Clinical Haematology. He is currently pursuing a PhD. Dr du Toit established his private practice at the Wits Donald Gordon Cellular + Immunotherapy Centre in 2019. He is currently the Bone Marrow Collection Director and Bone Marrow Transplant Physician at the Wits Donald Gordon Cellular + Immunotherapy Centre which is currently in the process of obtaining JACIE accreditation under the direction of Dr Jackie Thomson, his colleague and Clinical Programme Director. He is passionate about bone marrow transplantation and believes in offering the best possible care to his patients and always going the extra mile. He enjoys running, nature and travelling.

Carlo Dufour (Italy)

Carlo Dufour works in G.Gaslini Research Children’s Hospital, Genova, Italy, the largest, multi specialist pediatric hospital of the country, where he chairs the Hemo-Onco- HSCT Department and the Hematology Unit where have seat the national Registry of Neutropenia, the national Registry of Alps and related disorders and the national Data Base of Fanconi Anemia. He founded the Marrow Failure Syndromes Study Group in the Italian Pediatric Hemato-Oncology Association (AIEOP).

He is author or co-author of over 250 international publications and text book chapters. He acted as editor of hematology textbooks including the 2019 edition of the European Society for Blood and Marrow Transplantation (EBMT) textbook. He acts as reviewer for top ranking international journals including New England Journal of Medicine, Journal of Clinical Oncology, Leukemia, Clinical Immunology and Blood. He served as Chairman of the Working Party of the Severe Aplastic Anemia (WPSAA) and as Board member of the EBMT. He currently serves as the chairman of the Scientific Working Group on Granulocyte and Constitutional Marrow Failure Disorders of the European Hematology Association (EHA). He is member of the Guidelines Committee of the EHA. In 2015 he received by the Fanconi Anemia Research Fund, INC (FARF) the discovery award for participating to the identification of gene FANCT. Since december 2019 is member of the Scientific Committee on Marrow Failures of the American Society of Hematology. In december 2019 he was awarded for scientific contribution in Fanconi Anemia by the Spanish “Fundacion en la Anemia de Fanconi”. In august 2020 has been awarded by the EBMT along with Prof Regis Peffault de Latour and prof Antonio Ristiano, with the Van Bekkum award, a recognition reserved to best scientific communication of the year, as Co PI of the prospective randomized trial RACE (Comparison of classical IST ± Eltombopag) in Severe Aplastic Anemia.
Federica Frenza (Italy)
Ematologia, Dipartimento di Biomedicina e Prevenzione, Università degli Studi di Roma Tor Vergata, Roma, Italia

Nico Gagelmann (Germany)
University Medical Center Hamburg in Germany

Sebastian Giebel (Poland)
Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice in Poland

Raffaella Greco (Italy)
Senior Physician in the Hematology and Blood/Marrow Transplant (BMT) Unit of the IRCCS San Raffaele Hospital in Milano, Italy. Hematologist involved in hematopoietic stem cell transplantation (HSCT) and cellular therapies in all spectrum of haematological cancers and non-malignant indications. Her expertise in this field encompasses allogeneic and autologous stem cell transplantation (for malignant and non-malignant diseases), cellular therapies, immune reconstitution, biomarkers, transplant complications (i.e graft versus host disease, infections).

Her career has been focused on several clinical research projects on HSCT and cellular therapies. She has (co-)authored many research articles in peer reviewed journal as well as reviews, book chapters and best-practice guidelines in the field. She has been significantly involved with the European Group for Blood and Marrow Transplantation (EBMT), as Autoimmune Diseases Working Party (ADWP) Chair, Scientific Council Representative with the Education Portfolio, active member of the ADWP and Cellular Therapy & Immunobiology Working Party (CTIWP).
Esra Gülderen (Türkiye)

Esra Gülderen, Resident Physician from Uludag University, Internal Medicine, Turkey, and an aspiring Hematologist specifically interested in immunobiology in the context of hematologic malignancies and cellular therapy. My interests in the clinic and cancer research are therapeutic vulnerabilities in hematologic malignancies and immune-mediated side effects.

Before my Residency, I worked as a translational Research-scientist in Munich, Germany focusing on the role of extracellular vesicles and coagulation in the vascular phase of metastases, awarded by Carl Duisberg Fellowship. During my Postdoctoral Fellowship in Prof Joseph Bertino's lab at Rutgers University, CINJ, I focused on the development of targeted therapeutics including ADCs in therapy resistant lymphomas, multiple myeloma and several solid tumors. My interest in stem cell transplantation started when I was a medical student at Hacettepe University, Ankara where I have done extracurricular research at PediStem and graduated with Honors. I acquired a better understanding in Hematologic malignancies and BMT during my residency and electives at my home university and MDACC. EBMT Trainee Committee member.

Carmelo Gurnari (Italy)

After graduating from Pavia (Italy) medical school in 2015 with a thesis on Pediatric Hematology/Oncology, Dr. Gurnari completed his training in Hematology at the University of Rome, Tor Vergata. He then decided to continue his education at Tor Vergata, and he is currently enrolled in a Ph.D program in “Immunology, Molecular Medicine and Applied Biotechnology”.

Simultaneously, Dr. Gurnari has spent the last 3 years working at the Department of Translational Hematology and Oncology Research of Cleveland Clinic (USA) where he has been focusing on the genomics of bone marrow failure disorders and myeloid neoplasia. His clinical and translational research expertise encompasses myeloid malignancies with a special focus on acute promyelocytic leukemia, myelodysplastic syndromes, VEXAS, and acute myeloid leukemia. Dr. Gurnari is a member of the European Hematology Association (EHA) for which serves as a Mentor of the Classical Master Class Program, and of the European Society for Blood and Marrow Transplantation (EBMT), and he is actively involved in the activities of the Trainee Committee.
He is also a member of other national and international societies such as the American Association for the Advancement of Science, the Italian Hematology Association and the International Paroxysmal Nocturnal Hemoglobinuria Interest Group. In these years, Dr. Gurnari has been awarded several international prizes such as the Tito Bastianello Young Investigator Award in MDS research and the ASH-IPIG Award for PNH research (2020 and 2022).

Patrick Hayden (Ireland)

Dr Hayden is a consultant haematologist and clinical lead for the Myeloma service at St James's Hospital in Dublin. He completed a fellowship at the Jerome Lipper Myeloma Centre at the Dana Farber Cancer Institute in Boston. He became a member of the International Myeloma Working Group in 2017 and was Secretary of the Chronic Malignancies Working Party (CMWP) of the European Society for Blood and Marrow Transplantation (EBMT) from 2018 to 2022. He is currently chair of the CMWP Plasma Cell Diseases subcommittee.

Candice Hendricks (South Africa)

Candice Hendricks is a Paediatric Clinical Haematologist currently pursuing a PhD in Medical Immunology at the Institute for Cellular and Molecular Medicine at the University of Pretoria. Her PhD work is characterising umbilical cord blood haematopoietic stem cells from HIV exposed infants that are HIV negative at birth. Her hope is to provide more African and South African patients access to life-saving stem cell transplantations, with and without cell and gene therapies, in dedicated paediatric transplantation units.

She believes this vision can be achieved by improving the number and diversity of South Africa’s stem cell donor population, improving clinical paediatric transplantation skills, increasing the academic, clinical and manufacturing capacity in the cell and gene therapy field and advocating for inclusivity of patients from both the public and private sectors to ensure all patients benefit equally.
Lidia Hurtado (Spain)
Institu Català Oncologia in Barcelona, Spain

Daphna Hutt (Israel)
Sheba Medical Center in Ramat Gan, Israel.

Angela Hwang (United Kingdom)
Angela is a haematology CAR-T clinical fellow from University College London Hospital. She completed her haematology training in Sydney, Australia at St Vincent's Hospital and has a special interest in allogeneic stem cell transplantation and cellular therapy.

Thomas Jezequel (France)
Advanced Practice Nurse in the Pediatric Hematology Department of the University Hospital of Nantes

Edward Jones (Ireland)
Irish haematology trainee currently working in St James's Hospital, Dublin, Ireland with a special interest in stem cell transplantation & cellular therapies. Passionate improving patient outcomes in this field.
Krzysztof Kalwak (Poland)

I graduated from Wroclaw Medical Academy in 1995 and attended research scholarships at the Universities of Tübingen and Ulm (Germany). During many years of work in the Department of Pediatric Hematology, Oncology and BMT in Wroclaw, I completed subsequent steps of my scientific career and became a full professor in 2014. I am a specialist in pediatrics, clinical immunology, pediatric oncology and hematology, and clinical transplantology.

In 2021, I became the chair of Department of Pediatric Hematology, Oncology and BMT, Supraregional Centre for Pediatric Oncology “Cape of Hope” at Wroclaw Medical University (PL) which hosts one of the largest pediatric transplant units in Europe. I have had the honor to be the director of the transplant program for 16 years now. In more than 25 years of clinical and scientific work I have gained comprehensive experience in pediatric HSCT, with special interest in pediatric leukaemias, primary immunodeficiencies (PIDs), inborn errors of metabolism and post-transplant infectious and non-infectious complications, which is reflected by a steady accrual of multiple peer-reviewed publications that I have authored or co-authored. I have been entrusted a position of National Coordinator for HSCT in PIDs and metabolic disorders, treatment of CML and congenital neutropaenia. I had the honor to be the first physician in Poland to use CAR-T cells in a pediatric patient (March 2020). Since then, 29 more children have been offered a salvage therapy with CAR-T cells. In 2022 I was ranked 43rd on the “List of top 100 most influential representatives of Polish medicine”.

Michelle Kenyon (United Kingdom)

Consultant Blood and Marrow Transplant Nurse, whose interests focus on improving the patient and caregiver experience during haematopoietic stem cell transplantation and supporting patients throughout their post-transplant recovery. Her research and service development interests centre on patient experience, psychosocial issues, treatment consequences and the unmet needs of those living with and beyond their diagnosis.
Her role also enables her to lead a team and teach regularly. As current President of the EBMT Nurses’ Group, she has a strong commitment to delivering education for nurses both nationally and internationally to benefit patient care. Michelle has two patient information books, which are used as the basis for informed consent for transplant recipients throughout the UK, and she is Co-editor of the first EBMT Textbook for Nurses.

Paweł Kiciński (Germany)

Dept. of Hematology & BMT, St. John Cancer Center, Lublin, Poland

Annika M Kisch (Sweden)

Annika has been working as a nurse in the field of haematology and stem cell transplantation since 1993, at Lund university hospital, Sweden. In 2015 she finalized her thesis, Allogeneic stem cell transplantation – Patients’ and sibling donors’ perspectives. Since then she is working with nursing research, development and education at the same department at the hospital, and she is also an Associated Professor at Lund University, Department of Health Sciences, with special research interest in person centered care. Since 2018 she is a member of the Nurses Group Research Committee EBMT, and since April 2021 the chair of this committee.

Daniel Kisielewski (Germany)

Klinikum Stuttgart Hospital in Germany
Katharina Kleinschmidt (Germany)

Dr. Katharina Kleinschmidt is a consultant of the Department of Hematology, Oncology and Stem Cell Transplantation at the Children’s Hospital in Regensburg, Germany. She received her medical degree from Ruprecht-Karls-University of Heidelberg, and completed her pediatric degree at the University Hospital of Bologna, Italy. She received specialized training in pediatric hematology and oncology at University Hospital Regensburg, Germany.

Dr. Kleinschmidt’s research interest is focused on curative options for hemoglobinopathies and transplant-related systemic endothelial complications such as VOD/SOS. She is author of numerous peer-reviewed articles published in Lancet Hematology and Bone Marrow Transplantation among others. She is a member of several professional associations, including the German Society of Pediatric Oncology and Hematology (GPOH), as well as EBMT. She has been confirmed in 2023 for her second term of Secretary to the Paediatric Diseases Working Party of the EBMT.

Nicolaus-Martin Kröger (Germany)

Dr. Nicolaus Kröger is Professor of Medicine and Medical Director of the Department of Stem Cell Transplantation at the University Medical Center Hamburg-Eppendorf, Germany. Prof. Kröger is board certified in Hematology-Oncology and Internal Medicine. From 2018 to 2022 he was President of the European Society of Blood and Marrow Transplantation (EBMT) and from 2012 to 2018 Chairman of the Chronic Malignancy Working Party of EBMT and from 2014 to 2018 Scientific Council Chair of EBMT.

He served also as chairman of the German Stem Cell Working Group (DAG-KBT) from 2014-2020 and is member of several editorial boards such as Blood, Haematologica, Bone Marrow Transplantation and Biology of Blood and Marrow Transplantation. He is Co-Editor of the EBMT Handbook and the EBMT/EHA CAR-T Cell Handbook and also member of numerous Scientific Committees such as ASH, EHA, and ESH.
He has received several awards for his work to date including the prestigious EBMT van Bekkum Award in 2015. In 2020 he was awarded as Doctor Honoris Causa from the University Belgrade. Prof. Kröger has published extensively in his area of expertise and has contributed to more than 800 publications in peer-reviewed journals such as NEJM, Lancet, JCO, JNCl, PNAS, Blood and Leukemia

Deepesh Lad (India)

MD, DM, Clinical Hematology, Fellowship in Leukemia/ Blood & Marrow Transplantation. Associate Professor, Department of Clinical Hematology & Medical Oncology. Postgraduate Institute of Medical Education and Research, India.

Elisa Linnea Lindfors Rossi (Italy)

Department of Cell Therapy and Allogenic Stem Cell Transplantation (CAST), Karolinska Comprehensive Cancer Center, Karolinska University Hospital, Stockholm, Sweden. Hematology, Department of Biomedicine and Prevention, Università degli studi di Roma Tor Vergata, Rome, Italy.

Karolina Magdalena Liszka (Poland)

Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, Wroclaw, Poland

Per Ljungman (Sweden)

Karolinska University Hospital in Stockhol, Sweden
Natalia Lorente del Río (Spain)

Natalia Lorente is a nurse with a career spanning over two decades. For almost fifteen years, Natalia worked at the Madrid Blood Center, focusing on apheresis and blood donors. Her expertise in these areas has been instrumental in ensuring safe and efficient blood collection procedures. In 2015, Natalia transitioned to the Gregorio Marañón Hospital in Madrid.

Her current responsibilities encompass a wide range of specialized areas, including blood donors, advanced cell therapy, apheresis, and the surveillance of blood components and transfusion. As a member of the Spanish Hematopoietic Transplantation Working Group (GETH), Natalia has actively contributed to the development of the Guide for patients and donors in Peripheral Blood Stem Cell Collection, as well as the creation of the Venous Access Guide. Moreover, she actively participates in the Hemovigilance Working Group of the Spanish Society of Transfusion Medicine and Advanced Cell Therapy (SETS).

Florent Malard (France)

Hôpital Saint-Antoine, AP-HP in Paris, France

Alexandra Martínez Roca (Spain)

Hematologist, currently working at Hospital Clinic of Barcelona, with a special interest in at-home/outpatient management, acute myeloid leukemia, and CAR-T cell. PhD student at Universitat de Barcelona.
Neema Mayor (United Kingdom)

Dr Neema Mayor is Head of Immunogenetics Research at the Anthony Nolan Research Institute and is an Honorary Lecturer in the Cancer Institute at University College London. She is a Section Editor for the journal HLA and is a member of the Editorial Board of Human Immunology and the International Journal for Immunogenetics. In addition, she is in her second term as a Councillor on the European Federation for Immunogenetics (EFI) Executive Committee.

Neema has worked at Anthony Nolan since 2001 as part of the Patient/Donor project, an on-going study that aims to identify how genetic and clinical factors of the patient and donor impact on haematopoietic cell transplant (HCT) outcome. She obtained her PhD from University College London while at Anthony Nolan in the group of Professor Steven Marsh. Her PhD studies demonstrated the impact of NOD2 polymorphisms on the risk of relapse and mortality for recipients of an unrelated donor HCT for an acute leukaemia. Neema’s research is currently focussed in two areas; firstly, the development and implementation of novel methods to detect genetic polymorphism and secondly, analysing the impact of HLA and non-HLA genetic variants on HCT outcome in the UK transplant population. Her current research projects are looking at how HLA matching at the level of resolution achievable with next- and third-generation sequencing methods impacts on the outcome of stem cell transplants, as well as using this technique to identify other genetic markers that may be associated with better outcome prognoses. Neema has been awarded the Invitrogen Young Scientist award at the 18th British Society for Histocompatibility and Immunogenetics (BSHI) meeting (2007), the van Bekkum Award at the European Society for Blood and Marrow Transplantation (EBMT) meeting (2007), and the International ASHI Scholar Award at the American Society for Histocompatibility and Immunogenetics (ASHI) meeting (2014) for her research work.

Donal McLornan (United Kingdom)

Dr Donal McLornan works as a consultant in the MPN, allogeneic transplant and CAR-T team at University College London Hospital, which has the largest transplant and academic CAR T program in the UK. He is the current chair of the Chronic Malignancy. Dr Donal McLornan works as a consultant in the MPN, allogeneic transplant and CAR-T team at University College London Hospital, which has the largest transplant and academic CAR T program in the UK.
He is the current chair of the Chronic Malignancy Working Party of the EBMT and is co-chair of the scientific council. Additionally, he is the vice chair of the Global Outreach Committee of EHA and chairs the UK wide National Cancer Research Institute MPN group. He has a particular interest in MPN, MPN/MDS overlap and allogeneic stem cell transplantation. His research and clinical trial portfolio focuses on Myelofibrosis and blast phase disease and he has published widely on these topics. Working Party of the EBMT and is co-chair of the scientific council. Additionally, he is the vice chair of the Global Outreach Committee of EHA and chairs the UK wide National Cancer Research Institute MPN group. He has a particular interest in MPN, MPN/MDS overlap and allogeneic stem cell transplantation. His research and clinical trial portfolio focuses on Myelofibrosis and blast phase disease and he has published widely on these topics.

Hilda Mekelenkamp (Netherlands)

Leiden University Medical Center in The Netherlands.

Mohamad Mohty (France)

Dr Mohamad Mohty is a full Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and Sorbonne University in Paris, France. He obtained his medical degree from the University of Montpellier, France, and PhD from the University of Marseille, France. He is also head of a translational research team (Inserm) at the Saint-Antoine Research Centre in Paris.

Dr Mohty is the past president of the European Society for Blood and Marrow Transplantation (EBMT), and the past chairman of the Acute Leukemia Working Party of the EBMT. He is also the founder and chairman of the International Academy for Clinical Hematology (IACH) and board member of the Intergroupe Francophone du Myelome (IFM). In addition to publishing more than 900 peer-reviewed articles in the field of stem cell transplantation, leukemia, and myeloma, Dr Mohty also serves as Editor-in-Chief of the journals Bone Marrow Transplantation and Clinical Hematology International. He also serves as an editor, board member, and/or reviewer across numerous other reputable journals.

Arnon Nagler (Israel)

Chaim Sheba Medical Center in Tel Hashomer, Israel.
Bénédicte Neven (France)
Necker Children Hospital in Paris, France. Inborn Errors working Party Chair.

Rosamaria Nitti (Italy)
Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital in Milano, Italy

Elin Öfverberg (Sweden)
I am a Pediatric nurse and JACIE Quality Manager at the Department of Pediatric Oncology in Gothenburg. One of four pediatric centers in Sweden performing stem cell transplants. I'm also a member of the EBMT Nurses Group, the Global Education Comitée since last year.

Maeve O'Reilly (United Kingdom)
The Queen Silvia Childrens Hospital, United Kingdom
Valentín Ortiz Maldonado (Spain)

Valentín Ortiz-Maldonado, MD, PhD received his medical degree from the National University of Cuyo, Argentina (2012) and completed his Haematology residency at the Hospital Clinic of Barcelona, in 2017 (University of Barcelona). He obtained a master's degree in haematopoietic transplantation from the University of Valencia (2017) and an expert degree in Immuno-Oncology from the University of Navarra (2019).

He achieved his PhD degree (cum laude) on the clinical development of varnimcabetagene autoleucel (ARI-0001), a fully academic CART19 product, for the treatment of CD19+ lymphoproliferative disorders (2022). Staff member of the Haematology Department at the Hospital Clinic of Barcelona (Spain). His focus of research is mainly on the clinical development of CAR-T therapies for haematological malignancies. His work helped in the achievement of the first approval by a European Regulatory Agency (AEMPS) of a fully academic CAR-T product through Hospital Exemption for adult patients with relapsed/refractory B-ALL. Currently involved in clinical research activities and is member of the Cellular Therapy and Immunobiology Working Party (CTIWP) of the European society of Blood and Marrow Transplantation (EBMT).

Annalisa Pavligianiti (Spain)

She received her medical degree and completed her residency in Hematology at University Campus Biomedico in Rome in 2014. She completed a university training (Diplôme Inter-universitaire) in Statistical Methodology and Clinical Research at the ‘CESAM-Centre d’enseignement de la statistique appliquée à la médecine et à la biologie médicale’, University Pierre and Marie Curie, (Paris, France) in 2016. From January to June 2014 she attended the Molecular Cytogenetics Unit of the Centro de Investigación del Cáncer in Salamanca, Spain, focused on cytogenetics and next generation sequencing for hematological disorders.
From 2015 she worked as a research physician at Eurocord, Hôpital Saint Louis, where she actively participated to international retrospective studies, and then as a clinical physician at Hôpital Saint Antoine (Paris, France), until June 2020, where she worked as a physician in the Bone Marrow Transplant Team. She joined the hematopoietic and stem cell transplantation and cellular therapies department in Institut Català d’Oncologia in Barcelona 2 years ago. She is author of 50 publications and she has participated as a speaker for several international conferences. Her research interests include clinical research, allogeneic cell transplantation for hematologic malignant diseases and autologous stem cell transplantation strategies.

Oscar M Pello (Spain)

Since 2018 QP/Technical Director Advanced Therapies Unit at the Marques de Valdecilla Foundation: JACIE accredited unit for hematopoietic stem cell processing and AEMPs accredited unit for ATMPs manufacturing. Since 2018 JACIE processing inspector.

Olaf Penack (Germany)
Charite Hospital in Berlin, Germany

Piotr Piętowski (Poland)
Dept. of Hematology & BMT, St. John Cancer Center, Lublin, Poland

José Luís Piñana (Spain)
Hospital Clinico Universitario de Valencia, Spain

Umberto Pizzano (Italy)
Hematology Stem Cell Transplantation Unit, University Hospital ASUFC, Udine, Italy
Marijke Quaghebeur (Belgium)
University Hospital Ghent, Belgium

Purushotham Ramachandran (United Kingdom)
Haematology Trainee, Dept of Paediatric Haematology and Stem cell transplant and cellular therapies in the Royal Victoria Infirmary, Newcastle Upon Tyne, UK

Nicolò Rampi (United Kingdom)
Department of Oncology and Oncohematology, University of Milan, Milan, Italy

Alexandros Rampotas (United Kingdom)
I am an MRC Clinical research training fellow currently working on developing cellular therapies and studying myeloproliferative neoplasms. I am a sub investigator in multiple clinical trials run at UCLH.

Kristin Rathje (Germany)
University Medical Center Hamburg-Eppendorf, Germany

Tuula Rintala (United Kingdom)
The Director for Advocacy and Quality of Care leads the JACIE Accreditation scheme as well as supporting GoCART Coalition and Advocacy function for the organisation.
Annalisa Ruggeri (Italy)
IRCCS San Raffaele Scientific Institute in Milan, Italy

Julia Ruiz Pato (Spain)
Julia Ruiz works as Headnurse and Quality Manager of the Oncology-Hematology and Bone Marrow Transplant Unit Niño Jesús Childrens´ Hospital in Madrid. Her recent background is leading a LTFU Nurse consultant. She is a pediatric nurse and obtained master’s degree in Hematopoietic Stem Cell Transplant by the University of Valencia. Julia is the nurse representative and nurse coordinator of the Spanish Nurses Group included in Spanish Society of Hematopoietic stem cell Transplantation (GETH). She is JACIE Inspector for Quality Management and chair of the EBMT Nurses´ Global Educational Committee.

Sandra Schönfeld (Switzerland)
University of Applied Sciences Bern in Basel, Switzerland

Petr Sedlacek (Czech Republic)
University Hospital Motol in Prague, Czech Republic
Alexandros Spyridonidis (Greece)
University of Patras in Greece

Marion Subklewe (Germany)
LMU University Hospital Munich, Germany

Anna Sureda (Spain)

Anna Sureda, (MD, PhD) is nowadays the Head of the Clinical Hematology Department of Institut Català d’Oncologia – Hospitalet, Barcelona. She had previously been a Senior Consultant in Hospital de la Santa Creu i Sant Pau, Barcelona (from January 1991 to December 2010) and a Senior Consultant focused in lymphomas and hematopoietic stem cell transplantation (HSCT) at Addenbrookes-Cambridge University Hospital, UK (December 2010 – December 2012). Anna Sureda has focused her career on clinical investigations into the treatment of Hodgkin’s lymphoma, non-Hodgkin’s lymphoma and multiple myeloma patients evaluating novel therapies such as immunotherapy combined with stem-cell transplantation.

Anna Sureda was appointed Chairperson of the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT) from March 2004 to March 2010 and Secretary of the same organization from March 2010 to March 2016. She was elected co-chair of the Lymphoma Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR) and has served the organization in this position from February 2015 to February 2019. She was subsequently appointed as member of a large non-US Transplant Center in the Advisory Committee of the CIBMTR (from February 2019). Anna Sureda is President of the Spanish Society of Hematopoietic Stem Cell Transplantation and Cellular Therapy (GETH-TC) and, from March 2022, President of the EBMT. Anna Sureda is regular reviewer of several peer reviewed journals (Blood, Annals of Oncology, Bone Marrow Transplantation, The Hematology Journal, The European Journal of Hematology y Annals of Hematology) and has co-authored more than 400 manuscripts.
Sally Thomas (United Kingdom)
Dr S. Thomas BA, BMBCh, MRCP, PhD, FRCPath (Haematology Trainee, Royal Hallamshire Hospital, Sheffield, UK).

Cristina Toffalori (Italy)
San Raffaele Scientific Institute in Milan, Italy

Sheila Torrado González (Spain)
I am a Paediatrician trained in Paediatric Haematology, Oncology and Haematopoietic Stem Cell Transplantation. I completed a 2-year Paediatric HSCT fellowship in Bristol, and I am currently working as a Locum Consultant in Paediatric HSCT in Hospital Sant Joan de Déu Barcelona. I am member of the EBMT Trainee Committee, and I have participated in EBMT educational meetings, in some of which I could contribute with presentation and discussion of complex clinical cases. My areas of interests are education and training in HSCT, Paediatric diseases, acute leukaemia and transplant complications.

Dominik Turkiewicz (Sweden)
University Hospital in Scania in Lund, Sweden

Lucas Vogt Cota (Brasil)
Bone marrow transplant resident physician at São Paulo University in Brazil

Tien Gen Wong (Malaysia)
Haematology Department, Hospital Ampang, Malaysia

Robert Wynn (United Kingdom)
Royal Manchester Children’s Hospital in United Kingdom
THANKS TO OUR SPONSORS!

Industry Symposium

Therakos
ECP Immunomodulation

Silver Partner

Vertex
The Science of Possibility

Meeting Supporter

neovii

Miltenyi Biotec